Drug intelligence / Profile preview

Lipikar Baume AP+

Development stage
Unknown
Lead developer
La Roche-Posay
Administration
Topical
01

Overview

Lipikar Baume AP+ is a lipid-replenishing emollient balm developed by La Roche-Posay (a brand of L'Oréal) specifically for the management of atopic dermatitis (AD) and extremely dry, itchy skin (xerosis). The formulation is distinguished by the inclusion of **Aqua Posae Filiformis**, a prebiotic lysate derived from the non-pathogenic bacterium *Vitreoscilla filiformis*, which is intended to rebalance the skin microbiome and improve barrier function. Other key active ingredients include **niacinamide** for its anti-inflammatory properties, **shea butter** for lipid replenishment, and **Microresyl** to limit the formation of *Staphylococcus aureus* biofilms. Clinical research has evaluated Lipikar Baume AP+ both as a primary prevention strategy in high-risk infants and as a supportive baseline therapy for adults with moderate-to-severe atopic dermatitis undergoing systemic treatments such as dupilumab, cyclosporine, or JAK inhibitors.

Brand names
Lipikar Baume AP+Lipikar Baume AP+MLipikar Balm AP
Other names
Lipikar AP+ MLipikar Baume AP+ balsamLipikar routine
02

Targets

HTR2C (5-hydroxytryptamine 2C receptor)HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)

Beyond the preview

Go deeper on Lipikar Baume AP+.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipikar Baume AP+.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call